{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:54:25Z","timestamp":1793987665021,"version":"4.8.0"},"reference-count":133,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Hyperuricemia, characterized by elevated serum uric acid levels, has been linked to cardiovascular diseases such as hypertension, atrial fibrillation, chronic kidney disease, heart failure, metabolic syndrome, and coronary artery disease. This relationship, however, is complex; while some studies indicate a strong association, others suggest that it may be influenced by confounding factors. The rising global prevalence of hyperuricemia underscores the necessity for a deeper understanding of its cardiovascular implications. Hyperuricemia results from an imbalance in uric acid production and excretion, driven by dietary factors, obesity, insulin resistance, and other conditions. Elevated uric acid levels contribute to cardiovascular risk through mechanisms such as inflammation, oxidative stress, endothelial dysfunction, and activation of the renin-angiotensin-aldosterone system. This review highlights the importance of ongoing research to clarify hyperuricemia\u2019s role in cardiovascular disease and suggests that urate-lowering therapies, such as xanthine oxidase inhibitors, may confer cardiovascular benefits; however, evidence remains conflicting. The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial indicated an increased risk of cardiovascular and all-cause mortality with febuxostat compared with allopurinol, raising safety concerns. In contrast, the Febuxostat versus Allopurinol Streamlined Trial (FAST) demonstrated that febuxostat was noninferior to allopurinol, with even lower all-cause mortality. These opposing findings emphasize the complexity of treatment decisions and the need for individualized management strategies for hyperuricemia. Clinical decisions should consider individual patient risks and characteristics. Ultimately, this comprehensive analysis aims to enhance prevention and management strategies for cardiovascular diseases related to hyperuricemia. The overview includes discussions on major studies such as the Framingham Heart Study, CARES, FAST, PRIZE, and FREED trials, examining their results. It explores whether hyperuricemia is a causal factor versus an associated risk factor and whether it serves as a marker or mediator of disease. Additionally, the review addresses novel biomarkers and predictive models, the management of hyperuricemia in the context of cardiovascular risk, the role of urate-lowering therapies in cardiovascular disease, variability in guidelines and recommendations, and the impact of hyperuricemia in special populations such as those with diabetes and chronic kidney disease. The cardiovascular risk associated with hyperuricemia across various demographics is also discussed. Furthermore, the review suggests that existing risk scores might be modified to include uric acid levels in patients with hyperuricemia.<\/jats:p>","DOI":"10.1097\/hpc.0000000000000388","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T11:00:43Z","timestamp":1741604443000},"page":"e0388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Hyperuricemia and Cardiovascular Risk: Insights and Implications"],"prefix":"10.1097","volume":"24","author":[{"given":"Abdalhakim","family":"Shubietah","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Awashra","sequence":"additional","affiliation":[{"name":"Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi","family":"Milhem","sequence":"additional","affiliation":[{"name":"Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghannam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Brookdale University Hospital Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moath","family":"Hattab","sequence":"additional","affiliation":[{"name":"Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Rajab","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Joseph\u2019s University Medical Center, Paterson, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroun","family":"Neiroukh","sequence":"additional","affiliation":[{"name":"Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massa","family":"Zahdeh","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nouri","sequence":"additional","affiliation":[{"name":"Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalrahman","family":"Assaassa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Sahni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Abu Rmilah","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"R1-20250822","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jjcc.2020.12.013","article-title":"Uric acid and cardiovascular disease: a clinical review.","volume":"78","author":"Saito","year":"2021","journal-title":"J Cardiol"},{"key":"R2-20250822","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3909\/ricm0889","article-title":"Hyperuricemia and cardiovascular disease.","volume":"18","author":"Palazzuoli","year":"2017","journal-title":"Rev Cardiovasc Med"},{"key":"R3-20250822","doi-asserted-by":"crossref","first-page":"19520","DOI":"10.1038\/srep19520","article-title":"Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis.","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"R4-20250822","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med"},{"key":"R5-20250822","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40620-014-0082-z","article-title":"Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling.","volume":"27","author":"Liu","year":"2014","journal-title":"J Nephrol"},{"key":"R6-20250822","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","article-title":"Gout and hyperuricaemia in the USA: prevalence and trends.","volume":"58","author":"Singh","year":"2019","journal-title":"Rheumatology"},{"key":"R7-20250822","first-page":"e14855","article-title":"Hyperuricemia and cardiovascular risk.","volume":"13","author":"Shahin","year":"2021","journal-title":"Cureus"},{"key":"R8-20250822","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8603164","article-title":"Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis.","volume":"2016","author":"Kushiyama","year":"2016","journal-title":"Mediators Inflamm"},{"key":"R9-20250822","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","article-title":"Physiological functions and pathogenic potential of uric acid: a review.","volume":"8","author":"El Ridi","year":"2017","journal-title":"J Adv Res"},{"key":"R11-20250822","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11906-013-0344-5","article-title":"Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?","volume":"15","author":"Soltani","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"R12-20250822","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI42344","article-title":"Uric acid transport and disease.","volume":"120","author":"So","year":"2010","journal-title":"J Clin Invest"},{"key":"R13-20250822","doi-asserted-by":"crossref","first-page":"1470380","DOI":"10.1155\/2021\/1470380","article-title":"The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors.","volume":"2021","author":"Liu","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"R14-20250822","first-page":"1045","article-title":"Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen.","volume":"27","author":"Lin","year":"2000","journal-title":"J Rheumatol"},{"key":"R15-20250822","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/13697137.2017.1369513","article-title":"The association of hyperuricemia and metabolic syndrome in Thai postmenopausal women.","volume":"20","author":"Techatraisak","year":"2017","journal-title":"Climacteric"},{"key":"R16-20250822","doi-asserted-by":"crossref","first-page":"e027089","DOI":"10.1161\/JAHA.122.027089","article-title":"Elevated uric acid is associated with new-onset atrial fibrillation: results from the Swedish AMORIS Cohort.","volume":"12","author":"Ding","year":"2023","journal-title":"JAHA"},{"key":"R17-20250822","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40885-020-00146-y","article-title":"Uric acid and cardiometabolic diseases.","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Hypertens"},{"key":"R18-20250822","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R19-20250822","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbamem.2018.01.006","article-title":"Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP\/ABCG2 expression in vascular endothelial cells.","volume":"1860","author":"Komori","year":"2018","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"R20-20250822","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction.","volume":"67","author":"Khosla","year":"2005","journal-title":"Kidney Int"},{"key":"R21-20250822","doi-asserted-by":"crossref","first-page":"2050313X241272678","DOI":"10.1177\/2050313X241272678","article-title":"Dramatic devastative complications in a patient with catastrophic antiphospholipid syndrome: a case report and literature review.","volume":"12","author":"Shakhshir","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"R22-20250822","doi-asserted-by":"crossref","first-page":"47","DOI":"10.17219\/acem\/38159","article-title":"Hyperuricemia is an independent predictive factor for left ventricular diastolic dysfunction in patients with chronic kidney disease.","volume":"24","author":"Gromadzi\u0144ski","year":"2015","journal-title":"Adv Clin Exp Med"},{"issue":"Supplement_1","key":"R23-20250822","doi-asserted-by":"crossref","first-page":"jez319.338","DOI":"10.1093\/ehjci\/jez319.338","article-title":"P658 impact of hyperuricemia on left ventricular longitudinal systolic function in uncomplicated hypertensive patients.","volume":"21","author":"Lembo","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R24-20250822","first-page":"483","article-title":"Association between low-grade inflammation and left ventricular diastolic dysfunction in patients with metabolic syndrome and hyperuricemia.","volume":"36","author":"Liu","year":"2020","journal-title":"Acta Cardiol Sin"},{"key":"R25-20250822","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","article-title":"Hyperuricemia and incident heart failure.","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R26-20250822","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2010.05.002","article-title":"Hyperuricemia predicts adverse outcomes in patients with heart failure.","volume":"151","author":"Hamaguchi","year":"2011","journal-title":"Int J Cardiol"},{"key":"R27-20250822","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejim.2008.04.007","article-title":"Hyperuricemia in acute heart failure. More than a simple spectator?","volume":"20","author":"Alimonda","year":"2009","journal-title":"Eur J Intern Med"},{"key":"R28-20250822","doi-asserted-by":"crossref","first-page":"770815","DOI":"10.3389\/fendo.2021.770815","article-title":"Hyperuricemia and the risk of heart failure: pathophysiology and therapeutic implications.","volume":"12","author":"Si","year":"2021","journal-title":"Front Endocrinol"},{"key":"R29-20250822","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.numecd.2019.12.008","article-title":"Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities.","volume":"30","author":"Wu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R30-20250822","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjcard.2017.06.057","article-title":"Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction.","volume":"120","author":"Palazzuoli","year":"2017","journal-title":"Am J Cardiol"},{"key":"R31-20250822","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5603\/CJ.a2018.0022","article-title":"Hyperuricemia and severity of coronary artery disease: An observational study in adults 35 years of age and younger with acute coronary syndrome.","volume":"26","author":"Lv","year":"2019","journal-title":"Cardiol J"},{"key":"R32-20250822","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.amjcard.2010.07.046","article-title":"Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).","volume":"106","author":"Brodov","year":"2010","journal-title":"Am J Cardiol"},{"key":"R33-20250822","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.amjcard.2018.11.027","article-title":"Implications of hyperuricemia in severe coronary artery disease.","volume":"123","author":"Zhang","year":"2019","journal-title":"Am J Cardiol"},{"key":"R34-20250822","first-page":"e17161","article-title":"Hyperuricemia in patients with coronary artery disease and its association with disease severity.","volume":"17","author":"Padda","year":"2021","journal-title":"Cureus"},{"key":"R35-20250822","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1309\/LMKDB9PBKZGUS20T","article-title":"Hyperuricemia and the presence and severity of coronary artery disease.","volume":"41","author":"Goodarzynejad","year":"2010","journal-title":"Lab Med"},{"key":"R36-20250822","doi-asserted-by":"crossref","first-page":"80688","DOI":"10.18632\/oncotarget.21079","article-title":"Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities.","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"R37-20250822","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/clc.23266","article-title":"The association between hyperuricemia and coronary artery calcification development: a systematic review and meta-analysis.","volume":"42","author":"Liang","year":"2019","journal-title":"Clin Cardiol"},{"key":"R38-20250822","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1536\/ihj.16-192","article-title":"Hyperuricemia and atrial fibrillation: possible underlying mechanisms.","volume":"57","author":"Maharani","year":"2016","journal-title":"Int Heart J"},{"key":"R39-20250822","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1016\/j.ijcard.2013.06.067","article-title":"The association between hyperuricemia, left atrial size and new-onset atrial fibrillation.","volume":"168","author":"Chao","year":"2013","journal-title":"Int J Cardiol"},{"key":"R40-20250822","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2016.11.268","article-title":"Hyperuricemia is an independent competing risk factor for atrial fibrillation.","volume":"231","author":"Kuwabara","year":"2017","journal-title":"Int J Cardiol"},{"key":"R41-20250822","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.numecd.2014.03.012","article-title":"Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in Taiwan.","volume":"24","author":"Chuang","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R42-20250822","doi-asserted-by":"crossref","first-page":"8172639","DOI":"10.1155\/2022\/8172639","article-title":"Hyperuricemia increases the risk of atrial fibrillation: a systematic review and meta-analysis.","volume":"2022","author":"Gao","year":"2022","journal-title":"Int J Endocrinol"},{"key":"R43-20250822","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40618-017-0729-4","article-title":"Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.","volume":"41","author":"Mantovani","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"R44-20250822","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.3390\/jcm12155034","article-title":"The relationship between hyperuricemia and echocardiographic parameters in patients with chronic atrial fibrillation.","volume":"12","author":"Jordhani","year":"2023","journal-title":"J Clin Med"},{"key":"R45-20250822","doi-asserted-by":"crossref","first-page":"183","DOI":"10.12669\/pjms.35.1.148","article-title":"Analysis of NT-proBNP and uric acid due to left ventricle hypertrophy in the patients of aortic valve disease: evaluation NT-proBNP and uric acid as markers of left ventricle hypertrophy.","volume":"35","author":"Jan","year":"2019","journal-title":"Pak J Med Sci"},{"key":"R46-20250822","doi-asserted-by":"crossref","first-page":"230.e1","DOI":"10.1016\/j.amjmed.2016.09.005","article-title":"Association between gout and aortic stenosis.","volume":"130","author":"Chang","year":"2017","journal-title":"Am J Med"},{"issue":"Supplement_2","key":"R47-20250822","doi-asserted-by":"crossref","first-page":"ehad655.1624","DOI":"10.1093\/eurheartj\/ehad655.1624","article-title":"Impact of single-valve and multiple-valve heart disease on long-term outcome in patients with chronic heart failure.","volume":"44","author":"Hu","year":"2023","journal-title":"Eur Heart J"},{"key":"R48-20250822","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","article-title":"Metabolic syndrome, diabetes, and hyperuricemia.","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"R49-20250822","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/db10-0916","article-title":"Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome.","volume":"60","author":"Baldwin","year":"2011","journal-title":"Diabetes"},{"key":"R50-20250822","first-page":"766","article-title":"[Relationship between hyperuricemia and metabolic syndrome].","volume":"66","author":"Yamasaki","year":"2008","journal-title":"Nihon Rinsho"},{"key":"R51-20250822","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/jcm8060837","article-title":"Women with metabolic syndrome and general obesity are at a higher risk for significant hyperuricemia compared to men.","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"key":"R52-20250822","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/hr.2013.137","article-title":"Hyperuricemia predicts future metabolic syndrome: a 4-year follow-up study of a large screened cohort in Okinawa, Japan.","volume":"37","author":"Nagahama","year":"2014","journal-title":"Hypertens Res"},{"key":"R53-20250822","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/annrheumdis-2014-206432","article-title":"When gout goes to the heart: does gout equal a cardiovascular disease risk factor?","volume":"74","author":"Singh","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R54-20250822","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets.","volume":"13","author":"So","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"R55-20250822","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12916-017-0922-5","article-title":"What makes gouty inflammation so variable?","volume":"15","author":"Terkeltaub","year":"2017","journal-title":"BMC Med"},{"key":"R56-20250822","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/art.1780340203","article-title":"Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout.","volume":"34","author":"Pascual","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R57-20250822","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.radcr.2024.11.041","article-title":"Beh\u00e7et\u2019s disease and factor V Leiden: a thrombogenic synergy causing Budd-Chiari syndrome.","volume":"20","author":"Awashra","year":"2025","journal-title":"Radiol Case Rep"},{"key":"R58-20250822","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/annrheumdis-2014-205252","article-title":"Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink.","volume":"74","author":"Clarson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R59-20250822","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","article-title":"Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.","volume":"67","author":"Annemans","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R60-20250822","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2474-12-103","article-title":"Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.","volume":"12","author":"Primatesta","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"R61-20250822","doi-asserted-by":"crossref","first-page":"2050313X241282383","DOI":"10.1177\/2050313X241282383","article-title":"Diagnosing Beh\u00e7et\u2019s disease in the presence of pulmonary a rtery aneurysm and systemic symptoms: a case report.","volume":"12","author":"Bani Odah","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"R62-20250822","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-020-02175-2","article-title":"Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study.","volume":"22","author":"Colantonio","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R63-20250822","doi-asserted-by":"crossref","first-page":"32220","DOI":"10.1038\/srep32220","article-title":"The risk of atrial fibrillation in patients with gout: a nationwide population-based study.","volume":"6","author":"Kuo","year":"2016","journal-title":"Sci Rep"},{"key":"R64-20250822","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2020.01.019","article-title":"Gout and progression of aortic stenosis.","volume":"133","author":"Adelsheimer","year":"2020","journal-title":"Am J Med"},{"key":"R65-20250822","doi-asserted-by":"crossref","first-page":"rjae633","DOI":"10.1093\/jscr\/rjae633","article-title":"Spontaneous splenic rupture as a primary manifestation of angiosarcoma: a case report.","volume":"2024","author":"Awashra","year":"2024","journal-title":"J Surg Case Rep"},{"key":"R66-20250822","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.11.051","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies.","volume":"232","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"key":"R67-20250822","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/aje\/kws002","article-title":"Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study.","volume":"176","author":"Krishnan","year":"2012","journal-title":"Am J Epidemiol"},{"key":"R68-20250822","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2459\/JCM.0000000000000347","article-title":"Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy.","volume":"18","author":"Capuano","year":"2017","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R69-20250822","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3899\/jrheum.140457","article-title":"Cardiovascular risk factors and comorbidities in patients with hyperuricemia and\/or gout: a systematic review of the literature.","volume":"92","author":"Van Durme","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"R70-20250822","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3390\/jcm10091829","article-title":"Hyperuricemia as a marker of reduced left ventricular ejection fraction in patients with atrial fibrillation: results of the POL-AF Registry Study.","volume":"10","author":"We\u0142nicki","year":"2021","journal-title":"J Clin Med"},{"key":"R71-20250822","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.numecd.2015.08.004","article-title":"A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients.","volume":"25","author":"Testa","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R72-20250822","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1016\/j.transproceed.2009.07.080","article-title":"Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients.","volume":"41","author":"Karbowska","year":"2009","journal-title":"Transplant Proc"},{"key":"R73-20250822","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsha.2010.03.004","article-title":"Hyperuricemia and its association with carotid intima-media thickness in hypertensive and non hypertensive patients.","volume":"22","author":"Elsayed","year":"2010","journal-title":"J Saudi Heart Assoc"},{"key":"R74-20250822","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1681\/ASN.2005050572","article-title":"Uric acid\u2013induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells.","volume":"16","author":"Kang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R75-20250822","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.3390\/jcm10102062","article-title":"Uric acid\u2014an emergent risk marker for thrombosis?","volume":"10","author":"\u021a\u0103poi","year":"2021","journal-title":"J Clin Med"},{"key":"R76-20250822","doi-asserted-by":"crossref","first-page":"f4262","DOI":"10.1136\/bmj.f4262","article-title":"Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts.","volume":"347","author":"Palmer","year":"2013","journal-title":"BMJ"},{"key":"R77-20250822","doi-asserted-by":"crossref","first-page":"e7729","DOI":"10.1371\/journal.pone.0007729","article-title":"Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. Berger JS, editor.","volume":"4","author":"Stark","year":"2009","journal-title":"PLoS One"},{"key":"R78-20250822","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1373\/clinchem.2007.094425","article-title":"Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83 683 Austrian Men.","volume":"54","author":"Strasak","year":"2008","journal-title":"Clin Chem"},{"key":"R79-20250822","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.2337\/dc08-0349","article-title":"Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI.","volume":"31","author":"Brandst\u00e4tter","year":"2008","journal-title":"Diabetes Care"},{"key":"R80-20250822","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3899\/jrheum.090736","article-title":"Changes in waist circumference and body mass index in relation to changes in serum uric acid in Japanese Individuals.","volume":"37","author":"Ishizaka","year":"2010","journal-title":"J Rheumatol"},{"key":"R81-20250822","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.semnephrol.2020.12.004","article-title":"Hyperuricemia in kidney disease: a major risk factor for cardiovascular events, vascular calcification, and renal damage.","volume":"40","author":"Ejaz","year":"2020","journal-title":"Semin Nephrol"},{"key":"R82-20250822","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors.","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"key":"R84-20250822","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2005.04.007","article-title":"Prognostic usefulness of serum uric acid after acute myocardial infarction (The Japanese Acute Coronary Syndrome Study).","volume":"96","author":"Kojima","year":"2005","journal-title":"Am J Cardiol"},{"key":"R85-20250822","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.atherosclerosis.2013.03.017","article-title":"Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.","volume":"228","author":"Ahluwalia","year":"2013","journal-title":"Atherosclerosis"},{"key":"R86-20250822","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2009.05.022","article-title":"Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.","volume":"54","author":"Nozaki","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R87-20250822","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/3832648","article-title":"Relationships between serum uric acid, malondialdehyde levels, and carotid intima-media thickness in the patients with metabolic syndrome.","volume":"2019","author":"Wu","year":"2019","journal-title":"Oxid Med Cell Longevity"},{"key":"R88-20250822","first-page":"e238210","article-title":"Does serum uric acid to creatinine ratio predict mortality risk in patients with heart failure?","volume":"51","author":"Xi","year":"2024","journal-title":"Tex Heart Inst J"},{"key":"R89-20250822","doi-asserted-by":"crossref","first-page":"12104","DOI":"10.1038\/s41598-017-12085-0","article-title":"Serum uric acid to creatinine ratio and risk of metabolic syndrome in saudi type 2 diabetic patients.","volume":"7","author":"Al-Daghri","year":"2017","journal-title":"Sci Rep"},{"key":"R90-20250822","doi-asserted-by":"crossref","first-page":"2050313X241252738","DOI":"10.1177\/2050313X241252738","article-title":"Focal necrosis of the falciform ligament as a rare cause of abdominal pain: a case report.","volume":"12","author":"Awashra","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"R91-20250822","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12933-016-0409-2","article-title":"Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.","volume":"15","author":"Oyama","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"R92-20250822","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/diseases4010012","article-title":"Uric acid for cardiovascular risk: Dr. Jekyll or Mr. Hide?","volume":"4","author":"Vassalle","year":"2016","journal-title":"Diseases"},{"key":"R93-20250822","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/heartjnl-2014-305683","article-title":"Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial.","volume":"100","author":"Higgins","year":"2014","journal-title":"Heart"},{"key":"R94-20250822","doi-asserted-by":"crossref","first-page":"e1003095","DOI":"10.1371\/journal.pmed.1003095","article-title":"Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial. Borghi C, editor.","volume":"17","author":"Tanaka","year":"2020","journal-title":"PLoS Med"},{"key":"R95-20250822","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout.","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"R97-20250822","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"R98-20250822","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.41638","article-title":"Reassessing the cardiovascular safety of febuxostat: implications of the febuxostat versus allopurinol streamlined trial.","volume":"73","author":"Choi","year":"2021","journal-title":"Arthritis Rheum"},{"key":"R99-20250822","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and CaRdiorenovascular Events PrEvEntion StuDy.","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"R100-20250822","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.3390\/ijms22179221","article-title":"Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease.","volume":"22","author":"Yanai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R101-20250822","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1016\/j.radcr.2024.08.118","article-title":"Adenocarcinoma of the appendix presenting as chronic small bowel obstruction: a case report.","volume":"19","author":"Sawaftah","year":"2024","journal-title":"Radiol Case Rep"},{"key":"R102-20250822","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12882-022-02850-3","article-title":"Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.","volume":"23","author":"Sapankaew","year":"2022","journal-title":"BMC Nephrol"},{"key":"R103-20250822","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000573","article-title":"The role of febuxostat in gout.","volume":"31","author":"Bardin","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R104-20250822","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.HYP.0000085858.66548.59","article-title":"Hyperuricemia in childhood primary hypertension.","volume":"42","author":"Feig","year":"2003","journal-title":"Hypertension"},{"key":"R105-20250822","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/heartjnl-2012-302535","article-title":"The role of uric acid in the pathogenesis of human cardiovascular disease.","volume":"99","author":"Kanbay","year":"2013","journal-title":"Heart"},{"key":"R106-20250822","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.radcr.2024.09.148","article-title":"Mixed connective tissue disease: a case of aggressive progression and multisystem involvement.","volume":"20","author":"Odah","year":"2025","journal-title":"Radiol Case Rep"},{"key":"R107-20250822","doi-asserted-by":"crossref","first-page":"e50046","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced glomerular function and prevalence of gout: NHANES 2009\u201310. Steinman TI, editor.","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS One"},{"key":"R108-20250822","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41440-021-00752-9","article-title":"Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.","volume":"45","author":"Kusunose","year":"2022","journal-title":"Hypertens Res"},{"key":"R109-20250822","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/hr.2014.75","article-title":"Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension.","volume":"37","author":"Kuwabara","year":"2014","journal-title":"Hypertens Res"},{"key":"R110-20250822","doi-asserted-by":"crossref","first-page":"rjae525","DOI":"10.1093\/jscr\/rjae525","article-title":"A rare case of gastric schwannoma mimicking GIST: diagnostic and therapeutic approach.","volume":"2024","author":"Sawafta","year":"2024","journal-title":"J Surg Case Rep"},{"key":"R111-20250822","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","article-title":"Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.","volume":"30","author":"Higgins","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"R112-20250822","doi-asserted-by":"crossref","first-page":"e007046","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose\u2013linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects.","volume":"7","author":"Wilcox","year":"2018","journal-title":"JAHA"},{"key":"R113-20250822","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials.","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R114-20250822","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.sjbs.2018.11.013","article-title":"Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis.","volume":"26","author":"Xin","year":"2019","journal-title":"Saudi J Biol Sci"},{"key":"R115-20250822","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1016\/j.radcr.2024.09.034","article-title":"Spontaneous angiomyolipoma rupture: a case of hemorrhagic shock and urgent embolization.","volume":"19","author":"Awashra","year":"2024","journal-title":"Radiol Case Rep"},{"key":"R116-20250822","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"R117-20250822","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.radcr.2024.09.138","article-title":"Unveiling postpartum pituitary apoplexy through atypical presentation: a case report and review of literature.","volume":"20","author":"Hamzeh","year":"2025","journal-title":"Radiol Case Rep"},{"key":"R118-20250822","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R119-20250822","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"key":"R120-20250822","first-page":"e63206","article-title":"Concurrent cardiac and renal anomalies in Waardenburg syndrome type 1: a report of a rare case.","volume":"16","author":"Awashra","year":"2024","journal-title":"Cureus"},{"key":"R121-20250822","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R122-20250822","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1016\/S0021-9258(19)40762-X","article-title":"Metabolism of dog gastric mucosa. Nucleotide levels in parietal cells.","volume":"250","author":"Sarau","year":"1975","journal-title":"J Biol Chem"},{"key":"R123-20250822","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R124-20250822","first-page":"e66033","article-title":"Cohen syndrome with complex medical complications: a case report.","volume":"16","author":"Milhem","year":"2024","journal-title":"Cureus"},{"key":"R125-20250822","doi-asserted-by":"crossref","first-page":"582680","DOI":"10.3389\/fphar.2020.582680","article-title":"Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective.","volume":"11","author":"Yu","year":"2020","journal-title":"Front Pharmacol"},{"key":"R126-20250822","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.atherosclerosis.2018.01.017","article-title":"Hyperuricemia as a prognostic factor after acute coronary syndrome.","volume":"269","author":"Lopez-Pineda","year":"2018","journal-title":"Atherosclerosis"},{"key":"R127-20250822","doi-asserted-by":"crossref","first-page":"8","DOI":"10.26442\/2075082X.2019.4.190686","article-title":"Consensus on patients with hyperuricemia and high cardiovascular risk treatment.","volume":"16","author":"Chazova","year":"2019","journal-title":"System Hyper"},{"key":"R128-20250822","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2215\/CJN.09420911","article-title":"Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality.","volume":"7","author":"Liu","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R129-20250822","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/2224-4018.135617","article-title":"Interpretation of the Chinese expert consensus: recommendations for diagnosis and treatment of asymptomatic hyperuricemia complicated with cardiovascular diseases.","volume":"2","author":"Guo","year":"2014","journal-title":"J Transl Intern Med"},{"key":"R130-20250822","doi-asserted-by":"crossref","first-page":"95","DOI":"10.20969\/VSKM.2022.15(1).95-106","article-title":"Hyperuricemia","volume":"15","author":"Amirov","year":"2022","journal-title":"VSKM"},{"key":"R131-20250822","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000105142","article-title":"The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease.","volume":"27","author":"Talaat","year":"2007","journal-title":"Am J Nephrol"},{"key":"R132-20250822","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00392-021-01849-4","article-title":"Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk.","volume":"110","author":"Li","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"R133-20250822","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.numecd.2013.03.005","article-title":"A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease.","volume":"23","author":"Ndrepepa","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R134-20250822","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5334\/gh.1102","article-title":"Hyperuricemia is related to the risk of cardiovascular diseases in ethnic chinese elderly women.","volume":"17","author":"Liu","year":"2022","journal-title":"Global Heart"},{"key":"R135-20250822","first-page":"e143","article-title":"Cardiovascular risk factors in ethnic populations within Canada: results from national cross-sectional surveys.","volume":"4","author":"Liu","year":"2010","journal-title":"Open Med"},{"key":"R136-20250822","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/eurjpc\/zwac275","article-title":"Serum uric acid significantly improves the accuracy of cardiovascular risk score models.","volume":"30","author":"Moshkovits","year":"2023","journal-title":"Eur J Prev Cardiol"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T14:00:38Z","timestamp":1755871238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000388","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}